Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Gerstein, Hertzel, MD Heart and Stroke Foundation of Ontario |
---|---|
Information provided by: | Gerstein, Hertzel, MD |
ClinicalTrials.gov Identifier: | NCT00140647 |
The purpose of this study is to determine if ramipril and/or rosiglitazone retard the progression of atherosclerosis as evaluated by serial carotid intermedial thickness measurements.
Condition | Intervention | Phase |
---|---|---|
Atherosclerosis Impaired Glucose Tolerance Isolated Impaired Fasting Glucose Cardiovascular Disease |
Drug: Ramipril Drug: Rosiglitazone |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study |
Official Title: | The Study of Atherosclerosis With Ramipril and Rosiglitazone |
Estimated Enrollment: | 1200 |
Study Start Date: | July 2001 |
Study Completion Date: | July 2006 |
STARR is a multi-centre, international, randomized controlled clinical trial with a 2x2 factorial design, that will evaluate the effects of ramipril and of rosiglitazone on atherosclerosis progression, as determined by B-mode carotid ultrasound (US). It is designed as a substudy of DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medications) Trial. The study is designed to enroll 1,200 study participants and follow is proposed for an average of 3.75 years.
SIGNIFICANCE OF THE PROPOSED RESEARCH: With regards to ramipril this study will provide important mechanistic data regarding potential benefits of ACE inhibitor therapy on atherosclerosis and by inference in reducing CV risk in a lower risk younger population than studied in previous trials. In this population a clinical outcome trial focusing primarily on CV events would be difficult to conduct due to the expected fairly low event rate. If the study on atherosclerosis is positive, this may provide a rational for therapy in this subset of patients without overt CVD or diabetes, but with impaired glucose tolerance or impaired fasting glucose.
Ages Eligible for Study: | 30 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | STARR |
Study First Received: | August 30, 2005 |
Last Updated: | August 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00140647 |
Health Authority: | United States: Food and Drug Administration |
atherosclerosis carotid artery ramipril rosiglitazone |
impaired glucose tolerance impaired fasting glucose diabetes prevention |
Arterial Occlusive Diseases Atherosclerosis Metabolic Diseases Hyperglycemia Glucose Intolerance Vascular Diseases |
Diabetes Mellitus Arteriosclerosis Metabolic disorder Glucose Metabolism Disorders Rosiglitazone Ramipril |
Hypoglycemic Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs Angiotensin-Converting Enzyme Inhibitors Enzyme Inhibitors |
Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Protease Inhibitors |